Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.62 +0.04 (+0.22%)
Streaming Delayed Price Updated: 3:54 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
News headline image
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients ↗
 
Via Benzinga
News headline image
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder ↗
The  
Via Benzinga
News headline image
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine ↗
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials. 
Via InvestorPlace
News headline image
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report ↗
 
Via Benzinga
News headline image
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference ↗
 
Via Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent... 
Via FinancialNewsMedia
News headline image
Takeda Announces Completion of Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Monday Markets News ↗
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
News headline image
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
News headline image
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
News headline image
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
Via Benzinga
News headline image
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
Via Benzinga
News headline image
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Best Russell 2000 Stocks to Buy Before they Rebound ↗
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices. 
Via InvestorPlace
News headline image
Why Are Seagen Shares Sinking Today? ↗
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
News headline image
Take a Leap Into Novavax Stock After Vaccine Sales Start ↗
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch. 
Via InvestorPlace
News headline image
A News Blizzard ↗
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
News headline image
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Worldwide Adoption of Novavax Vaccines Makes It a Winner ↗
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.